First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector

for the IPCAVD006/RV380/HIV-V-A002 Study Group

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Background Mosaic immunogens are bioinformatically engineered human immunodeficiency virus type 1 (HIV-1) sequences designed to elicit clade-independent coverage against globally circulating HIV-1 strains. Methods This phase 1, double-blinded, randomized, placebo-controlled trial enrolled healthy HIV-uninfected adults who received 2 doses of a modified vaccinia Ankara (MVA)-vectored HIV-1 bivalent mosaic immunogen vaccine or placebo on days 0 and 84. Two groups were enrolled: those who were HIV-1 vaccine naive (n = 15) and those who had received an HIV-1 vaccine (Ad26.ENVA.01) 4-6 years earlier (n = 10). We performed prespecified blinded cellular and humoral immunogenicity analyses at days 0, 14, 28, 84, 98, 112, 168, 270, and 365. Results All 50 planned vaccinations were administered. Vaccination was safe and generally well tolerated. No vaccine-related serious adverse events occurred. Both cellular and humoral cross-clade immune responses were elicited after 1 or 2 vaccinations in all participants in the HIV-1 vaccine-naive group. Env-specific responses were induced after a single immunization in nearly all subjects who had previously received the prototype Ad26.ENVA.01 vaccine. Conclusions No safety concerns were identified, and multiclade HIV-1-specific immune responses were elicited. Clinical Trials Registration NCT02218125.

Original languageEnglish
Pages (from-to)633-644
Number of pages12
JournalJournal of Infectious Diseases
Volume218
Issue number4
DOIs
StatePublished - 13 Jul 2018
Externally publishedYes

Keywords

  • HIV vaccine
  • immunogenicity
  • modified vaccinia Ankara
  • mosaic immunogens
  • safety

Fingerprint

Dive into the research topics of 'First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector'. Together they form a unique fingerprint.

Cite this